Lymphnodal recurrences in ovarian cancer: safe techniques in the minimally invasive approach

Lymph node recurrence accounts for 12%–37% of ovarian cancer relapses. It is considered more indolent compared with parenchymal and peritoneal disease and more suited to take advantage of surgical rather than medical treatment.[1][1] According to recent clinical trials, surgery has been confirmed